Literature DB >> 12145433

Chlorpheniramine is no more effective than placebo in relieving the symptoms of childhood atopic dermatitis with a nocturnal itching and scratching component.

J Munday1, R Bloomfield, M Goldman, H Robey, G J Kitowska, Z Gwiezdziski, A Wankiewicz, R Marks, F Protas-Drozd, M Mikaszewska.   

Abstract

BACKGROUND: Childhood atopic dermatitis (AD) is a common disorder affecting 15% of children aged over 18 months. AD is associated with intense nocturnal itching. The central sedative effect of antihistamines is thought to be useful in interrupting the itching cycle and may prevent exacerbations.
OBJECTIVE: A multi-centred, double-blind, placebo-controlled study was carried out in 155 children to evaluate chlorpheniramine in alleviating symptoms of AD.
METHODS: Assessments were carried out over a 4-week study period consisting of 3 visits to out-patient clinics. During the visits the severity of AD and itching was rated using a series of visual analogue scale (VAS) and 5-point rating scales.
RESULTS: The use of chlorpheniramine resulted in no greater alleviation of AD symptoms than placebo.
CONCLUSIONS: The findings contradict conventional wisdom that the sedative effect of earlier-generation antihistamines alleviates symptoms of AD. The study also indicates that the use of antihistamines in AD does not affect the amounts of topical treatment used over the short term. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12145433     DOI: 10.1159/000063138

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  9 in total

1.  Spontaneous scratching behaviour in DS-Nh mice as a possible model for pruritus in atopic dermatitis.

Authors:  T Yoshioka; I Hikita; M Asakawa; T Hirasawa; M Deguchi; T Matsutani; H Oku; T Horikawa; A Arimura
Journal:  Immunology       Date:  2006-07       Impact factor: 7.397

Review 2.  Frontiers in pruritus research: scratching the brain for more effective itch therapy.

Authors:  Ralf Paus; Martin Schmelz; Tamás Bíró; Martin Steinhoff
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

Review 3.  Oral H1 antihistamines as monotherapy for eczema.

Authors:  Christian J Apfelbacher; Esther J van Zuuren; Zbys Fedorowicz; Aldrin Jupiter; Uwe Matterne; Elke Weisshaar
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

4.  Association of the histamine N-methyltransferase C314T (Thr105Ile) polymorphism with atopic dermatitis in Caucasian children.

Authors:  Mary Jayne Kennedy; Jennifer A Loehle; Angela R Griffin; Mark A Doll; Gregory L Kearns; Janice E Sullivan; David W Hein
Journal:  Pharmacotherapy       Date:  2008-12       Impact factor: 4.705

5.  Update on the management of chronic eczema: new approaches and emerging treatment options.

Authors:  Hobart W Walling; Brian L Swick
Journal:  Clin Cosmet Investig Dermatol       Date:  2010-07-28

Review 6.  Sleep Disturbances and Atopic Dermatitis: Relationships, Methods for Assessment, and Therapies.

Authors:  Fatima Bawany; Carrie A Northcott; Lisa A Beck; Wilfred R Pigeon
Journal:  J Allergy Clin Immunol Pract       Date:  2020-12-13

7.  Guidelines on Management of Atopic Dermatitis in India: An Evidence-Based Review and an Expert Consensus.

Authors:  Murlidhar Rajagopalan; Abhishek De; Kiran Godse; D S Krupa Shankar; Vijay Zawar; Nidhi Sharma; Samipa Mukherjee; Aarti Sarda; Sandipan Dhar
Journal:  Indian J Dermatol       Date:  2019 May-Jun       Impact factor: 1.494

8.  Oral H1 antihistamines as 'add-on' therapy to topical treatment for eczema.

Authors:  Uwe Matterne; Merle Margarete Böhmer; Elke Weisshaar; Aldrin Jupiter; Ben Carter; Christian J Apfelbacher
Journal:  Cochrane Database Syst Rev       Date:  2019-01-22

9.  Extracellular signal-regulated kinase (ERK) activation is required for itch sensation in the spinal cord.

Authors:  Ling Zhang; Guan-Yu Jiang; Ning-Jing Song; Ying Huang; Jia-Yin Chen; Qing-Xiu Wang; Yu-Qiang Ding
Journal:  Mol Brain       Date:  2014-04-03       Impact factor: 4.041

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.